Digital presence carrying credibility before there is a product.
Biotech companies often need their digital presence to carry real credibility to investors, partners and a scientific community before there is a commercial product to point to, which is a different job than marketing an existing portfolio.
Without a marketed product, a biotech’s site is evaluated on the strength of its science, team and pipeline presentation. Investors and scientific partners check claims closely, and vague or inflated language is caught and damages credibility fast.
A pipeline and corporate presentation built for genuine scrutiny, content that speaks credibly to both scientific and investor audiences, and a digital presence that scales as the company moves through funding rounds and eventually toward commercialisation.
Your scientific claims and investment thesis come from your team and leadership; what we add is the structure and design that presents them with the precision an investor or partner expects, never promotional gloss.
The scope our work with biotech companies has operated within.
The build priorities before a commercial product differ from an established company. Here is what biotech companies most often need.
How this work is approached specifically for Biotech.
What comes up when building for a clinical-stage company.
Not as a replacement for a secure data room, but it can carry the public-facing layer that due diligence usually starts from — pipeline overview, publication list, leadership credentials — so a prospective partner or investor arrives at deeper conversations already informed. See investor deck design for the material built alongside the site for that stage of fundraising.
Yes, and this is common enough in biotech that we build for it by default — a pipeline page can show a therapeutic area or modality without naming a compound, so investors and partners see breadth without you disclosing anything your legal team has not cleared for public release. We adjust the level of detail per asset as programs mature and clearances change.
Yes — see investor deck design for that deliverable, which we frequently build in parallel with the website since both draw on the same underlying pipeline and team material. Keeping them in sync matters in biotech specifically, since investors and website visitors are often the same audience checking the two documents against each other for consistency.
No — this is the normal starting point for most biotech companies we work with, not an exception we accommodate occasionally. The site is built to establish credibility through pipeline depth, scientific leadership, and publication record rather than product claims, which is exactly the evidence a partner or investor is looking for before any product exists.
Related sectors worth reviewing alongside biotech.
A pipeline or company story that needs to withstand real scrutiny. Tell us your stage and we will tell you how we would approach it for a biotech company.